As shown in Figure 7D, CD4+ T-cell activation (including dendritic cell (DCs) ratio and expression of human leukocyte antigen (HLA)-II), CD4+ T-cell function (including T-cell co-stimulation, T helper cell level, and type II interferon response), and levels of macrophages, mast cells, HLA-I, T follicular helper cells (Tfh), type 2 T helper (Th2) cells, CCR, and checkpoint and tumor-infiltrating lymphocytes (TIL) were significantly lower in the BCBM group than those in the BC group. The gene discussed is CD4; the disease is breast cancer.